
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 28 years ago
Participating Facultyover 28 years ago
Current Approaches to Osteoporosis Preventionover 28 years ago
Patient-Provider Decisions About Long-Term Therapyover 28 years ago
Potential Impact of Emerging Therapies on Osteoporosis Preventionover 28 years ago
An Emerging Approach to Osteoporosis Preventionover 28 years ago
CME Quizover 28 years ago
Selected Abstractsover 28 years ago
Bibliography





